INJECTION SCHEMES Russian patent published in 2022 - IPC A61K38/04 A61K38/12 A61P27/02 

Abstract RU 2770099 C2

FIELD: medicine; ophthalmology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology; it is intended for the treatment of a complement-mediated ocular disorder, namely age-related macular dystrophy (hereinafter – AMD). A method for the treatment of a complement-mediated ocular disorder includes the injection to a subject who needs it of a long-acting compstatin analog (hereinafter – LACA). The specified LACA contains a clearance-reducing fragment connected to two compstatin analog fragments, wherein each compstatin analog fragment contains cyclic peptide with an amino acid sequence represented in SEQ ID NO: 28, elongated with lysin residue at C-end, wherein lysin residue is separated from a cyclic part with 8-amino-3,6-dioxaoctanoic acid (AEEAc)-spacer. The specified clearance-reducing fragment contains polymer, wherein each polymer end is bound to an amino group of a side chain of lysin residue of one of compstatin analog fragments via carbamate, and polymer is PEG with an average molecular weight of 40 kDa. The specified complement-mediated ocular disorder is AMD. The specified treatment includes intravitreal injection once a month or once every two months of the specified LACA to the eye of the specified subject in the amount from 10 mg to 20 mg. In other embodiments, the use of LACA in the treatment of AMD, and the use of a single dosed form of LACA in the treatment of AMD in a subject who needs it are presented.

EFFECT: use of the group of inventions provides for a new therapeutic mode for the effective treatment of a complement-mediated ocular disorder, such as AMD.

25 cl, 12 dwg, 12 tbl, 28 ex

Similar patents RU2770099C2

Title Year Author Number
DOSING SCHEMES AND CORRESPONDING COMPOSITIONS AND METHODS 2018
  • Grossi, Federiko
  • Deshatelets, Paskal
  • Fransua, Sedrik
  • Dzhonson, Patrik
  • Vega, Karolina
RU2779495C2
CELL-REACTIVE COMPOSTATIN ANALOGUES, LONG-ACTING COMPSTATIN ANALOGUES OR COMPUTED EFFECT ANALOGUES OF TARGETED ACTION AND RELATED COMPOSITIONS AND METHODS 2013
  • Fransua Sedrik
  • Deshatele Paskal
RU2705215C2
CELL-REACTIVE COMPSTATIN ANALOGS, LONG-ACTING COMPSTATIN ANALOGS, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF 2012
  • Fransua Sedrik
  • Deshatele Paskal
RU2653439C9
PROLONGED DELIVERY OF COMPSTATIN ANALOGUES FROM GELS 2008
  • Fransua Sedrik
  • Deshatelets Paskal'
  • Olson Pol
RU2505311C2
POTENT COMPSTATIN ANALOGS 2012
  • Lembriz Dzhon D.
  • Katragadda Madan
RU2656102C2
EFFICIENT COMPSTATIN ANALOGUES 2006
  • Lehmbriz Dzhon D.
  • Katragadda Madan
RU2474586C2
METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS 2017
  • Dyupon, Dzhejkob
  • Parmar, Khema
RU2765410C2
SURVIVIN-TARGETED ANTI-CANCER VACCINES AND APPLICATIONS THEREOF 2018
  • Yan, Jian
  • Slager, Anna
  • Garman, Bradley
  • Cooch, Neil
RU2776949C2
OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES 2016
  • Koenig Patrick
  • Lee Chingwei Vivian
  • Rajagopal Karthikan
  • Famili Amin
  • Fuh Germaine
RU2763916C2
HYBRID CARRIERS FOR DELIVERY OF NUCLEIC ACIDS 2017
  • Baumkhof, Patrik
  • Tile-Zyus, Karolin
  • Rejman, Joanna
RU2751001C2

RU 2 770 099 C2

Authors

Grossi, Federiko

Deshatelets, Paskal

Fransua, Sedrik

Dates

2022-04-14Published

2016-10-07Filed